Novartis: Adenocarcinoma of Lung trials
The registry lists 16 Adenocarcinoma of Lung studies with Novartis as lead sponsor. 1 are open to participants now and 8 have results posted.
Phase 1 2Phase 2 9Phase 3 2No phase 3(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South KoreaRecruitingNCT05703516
- LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib.CompletedNCT02450903Phase 2Results posted
- Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)CompletedNCT02414139Phase 2Results posted
- A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung CancerCompletedNCT02276027Phase 2Results posted
- LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and CrizotinibCompletedNCT01828112Phase 3Results posted
- LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung CancerCompletedNCT01828099Phase 3Results posted
- LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung CancerCompletedNCT01685138Phase 2Results posted
- An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR MutationsTerminatedNCT01646125Phase 2Results posted
- A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi TreatmentCompletedNCT01610336Phase 2Results posted
- Managed Access Programs for INC280, CapmatinibNo longer availableNCT04741789
- Managed Access Program Cohort Treatment Plan CTMT212X2002I to Provide Access to Trametinib and Dabrafenib Combination Therapy for Patients With BRAF V600 Mutation-positive Advanced Non-Small Cell Lung CancerNo longer availableNCT04507919
- A Phase II, Open-Label, Multicenter Study of Capmatinib in Subjects With MET Exon 14 Skipping Mutation Positive, Advanced, NSCLC With Brain MetastasesWithdrawnNCT04460729Phase 2
- Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC)WithdrawnNCT03240393Phase 2
- A Phase Ib Study of LXH254-centric Combinations in NSCLC or MelanomaTerminatedNCT02974725Phase 1
- A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)CompletedNCT02900664Phase 1
- Study of Vintafolide (MK-8109, EC145) in Participants With Progressive Adenocarcinoma of the Lung (MK-8109-008, EC-FV-03)CompletedNCT00511485Phase 2